Literature DB >> 16354331

Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma.

Steven D Mawhorter1, Anne Sierk, Susan M Staugaitis, Robin K Avery, Ronald Sobecks, Richard A Prayson, Gary W Procop, Belinda Yen-Lieberman.   

Abstract

West Nile virus (WNV) infections are potentially life threatening in immunocompromised hosts. Currently, the best diagnostic test is serology. Reverse-transcriptase polymerase chain reaction (RT-PCR) testing has a role, but, because WNV is a cell-associated neurotropic virus, RT-PCR results are frequently negative even in cases of active infection. We present a case in which serology results were persistently negative because the patient was immunocompromised following lymphoma treatment. The role of humoral immunity in resolution of WNV is also discussed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16354331     DOI： 10.3816/CLM.2005.n.053

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN： 1557-9190


  10 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

2.  Persistent B-cell depletion after rituximab for thrombocytopenic purpura.

Authors:  Gianni Bisogno
Journal:  Eur J Pediatr       Date:  2006-08-03       Impact factor: 3.183

3.  Arenaviruses and West Nile Virus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

Authors:  Judith A Anesi; Fernanda P Silveira
Journal:  Clin Transplant       Date:  2019-05-23       Impact factor: 2.863

Review 4.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

5.  Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients.

Authors:  Marilyn E Levi; Dianna Quan; Joseph T Ho; B K Kleinschmidt-Demasters; Kenneth L Tyler; Todd J Grazia
Journal:  Clin Transplant       Date:  2009-08-03       Impact factor: 2.863

Review 6.  Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis.

Authors:  Simone Lanini; Aoife C Molloy; Paul E Fine; Archibald G Prentice; Giuseppe Ippolito; Christopher C Kibbler
Journal:  BMC Med       Date:  2011-04-12       Impact factor: 8.775

7.  Fatal Eastern Equine Encephalitis in a Patient on Maintenance Rituximab: A Case Report.

Authors:  Isaac H Solomon; Pedro D S C Ciarlini; Sandro Santagata; Asim A Ahmed; Umberto De Girolami; Sashank Prasad; Shibani S Mukerji
Journal:  Open Forum Infect Dis       Date:  2017-02-12       Impact factor: 3.835

8.  West Nile Encephalitis, an Unusual Infection in a Chronic Lymphocytic Leukemia Patient.

Authors:  Manuel R Espinoza-Gutarra; Sherri L Cervantez; Zohra Nooruddin
Journal:  Case Rep Hematol       Date:  2018-10-14

9.  West Nile Virus Infection in the Immunocompromised Patient.

Authors:  Marilyn E Levi
Journal:  Curr Infect Dis Rep       Date:  2013-11-15       Impact factor: 3.663

10.  West Nile Virus Central Nervous System Infection in Patients Treated With Rituximab: Implications for Diagnosis and Prognosis, With a Review of Literature.

Authors:  Sejal Morjaria; Esther Arguello; Ying Taur; Kent Sepkowitz; Vaios Hatzoglou; Ajay Nemade; Marc Rosenblum; Marcela S Cavalcanti; M Lia Palomba; Anna Kaltsas
Journal:  Open Forum Infect Dis       Date:  2015-09-19       Impact factor: 3.835
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.